Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study
PLOS One · 2025
DOI: 10.1371/journal.pone.0323229 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, 2025. Verfasst von Mohammad Movahedi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital Research Insitute, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Herpes Zoster, Patient Acceptance of Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals.
Abstract (Originalsprache)
Background
Herpes zoster (HZ) infection is a significant concern among seniors and immunosuppressed patients including those with rheumatoid arthritis (RA). We aimed to compare healthcare utilization (HCU) and mortality in RA patients with and without HZ.
Methods
Patients from the Ontario Best Practices Research Initiative (OBRI) a clinical cohort (2008–2020) were linked to the Institute for Clinical Evaluative Sciences (ICES), a population health database. Each HZ patient was matched to four non-HZ patients based on sex, age, and HZ diagnosis date. The incidence of primary (HCU including hospitalization, Emergency Department (ED) visits, physician visits) and secondary (mortality and chronic clinical conditions) outcomes was calculated for each cohort, along with the impact of disease activity, patient-reported outcomes, and RA medication on these outcomes.
Results
The study included 269 RA patients with and 1072 without HZ. At index date (HZ diagnosis) patients with HZ were less likely to have private health insurance (45.7% vs. 56.5%) and more prone to use biologics (30.9% vs. 26.8%) and JAK inhibitors (3.7% vs. 2.6%). Hospitalization/ED visits and mortality were higher in HZ patients, but these differences were not statistically significant after adjusting for other factors. HZ patients had significantly more physician visits (adj IRR: 1.17; 95% CI: 1.03–1.33). Female sex and lower CDAI were associated with fewer physician visits. JAK inhibitor use was associated with increased mortality (adj HR: 4.73, 95% CI: 1.68, 13.4).
Conclusion
HCU was higher in RA patients with HZ, particularly in physician visits. Disease activity, patient reported outcomes and RA medication used did not have an impact on HCU and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Toronto General Hospital Research Insitute, University Health Network, Toronto, Ontario, Canada.
- Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Mohammad Movahedi
Förderung
- GlaxoSmithKline Biologicals
Zitieren
APA
Movahedi, M., Cesta, A., Li, X., Tatangelo, M. R., Bombardier, C., & OBRI investigators (2025). Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0323229
Vancouver
Movahedi M, Cesta A, Li X, Tatangelo MR, Bombardier C, OBRI investigators. Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study. PLOS One. 2025. doi:10.1371/journal.pone.0323229
BibTeX
@article{Movahedi2025,
author = {Movahedi, Mohammad and Cesta, Angela and Li, Xiuying and Tatangelo, Mark Robert and Bombardier, Claire and OBRI investigators, OBRI investigators},
title = {Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0323229}
}
EUVIMED